Abstract
Purpose :
To investigate the population-based incidence of ocular tumors in a single U.S. Midwestern county population.
Methods :
A retrospective review was conducted of all residents of Olmsted County, Minnesota diagnosed with any ocular tumor from January 1, 2006 to December 31, 2015. International Classification of Diseases, 9th and 10th Edition codes associated with ocular tumors were searched using the Rochester Epidemiology Project, a record-linkage system that captures virtually all medical care provided in this single Midwestern U.S. county population. Medical records were reviewed to confirm diagnoses. Age- and sex-adjusted incidence rates were calculated and adjusted to the 2010 U.S. White population.
Results :
There were 1,852 incident cases of ocular tumors during the 10-year study period, of which 948 (51.2%) were intraocular, 717 (38.7%) were extraocular/orbital, and 187 (10.1%) were ocular surface. Females accounted for 1,017 (54.9%) cases and 1,685 (91.0%) subjects were White. The overall age- and sex-adjusted incidence rate of all ocular tumors was 142.67 per 100,000 per year (95% confidence interval [CI]: 136.12 to 149.22). Benign tumors accounted for 1,584 (85.5%) cases, while 268 (14.5%) were malignant. Among benign neoplasms, the most frequent intraocular, extraocular/orbital, and ocular surface tumors were choroidal nevus in 837 (52.8%) cases, epidermal inclusion cyst in 264 (16.7%), and conjunctival nevus in 75 (4.7%), respectively. The most common malignant neoplasm was basal cell carcinoma in 182 (67.9%) subjects. The incidence rate of benign tumors was 120.80 per 100,000 per year (95% CI: 114.80 to 126.80), compared to 21.87 per 100,000 per year (95% CI: 19.25 to 24.50) for malignant tumors. Incidence rate for all ocular tumors overall increased with age (p<0.001). No difference in ocular tumor incidence rate existed between sexes (p=0.13). The incidence rate in adults (≥18 years old) was 137.28 per 100,000 per year (95% CI: 130.83 to 143.73), compared to incidence in pediatric patients of 5.39 per 100,000 per year (95% CI: 4.25 to 6.53).
Conclusions :
This population-based investigation may provide a more accurate assessment of ocular oncology epidemiology, demographics, and risk factors compared to referral center or claims data-based studies and may assist clinicians in formulating their differential diagnosis when encountering ocular neoplasms.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.